Shares of CEL-SCI Has Fallen Below Previous 52-Week Low
CEL-SCI (AMEX:CVM) traded today at a new 52-week low of $1.08. Approximately 951,000 shares have changed hands today, as compared to an average 30-day volume of 811,000 shares.
CEL-SCI (AMEX:CVM) is currently priced 35.6% above its average consensus analyst price target of $0.73. CEL-SCI shares should first meet resistance at the 50-day moving average (MA) of $1.98 and find additional resistance at the 200-day MA of $2.42.
Over the past year, CEL-SCIhas traded in a range of $1.08 to $3.90 and are now at $1.13. Over the last five market days, the 200-day moving average (MA) has gone down 1.1% while the 50-day MA has declined 1.5%.
CEL-SCI Corporation researches and develops certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI is also developing other products. The Company is currently targeting diseases such as AIDS, herpes simplex, malaria, tuberculosis, prostate cancer, and breast cancer.
SmarTrend recommended that its subscribers protect gains by selling shares of CEL-SCI on August 28th, 2013 by issuing a Downtrend alert when the shares were trading at $1.95. Since that call, shares of CEL-SCI have fallen 31.8%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
Keywords: 52 week high/lows amex:cvm cel-sci